In future clinical applications, in addition to the use of cisplatin, Nimotuzumab, and Bevacizumab alone in the treatment of lung cancer, the combination of NR4A1-targeted drugs with monoclonal antibody chemotherapy may provide a better treatment option for patients. Here, NR4A1 is linked to lung cancer.